Monoclonal Antibody to Neutrophil Specific Antigen 1 (NB1)
Code | Size | Price |
---|
MAA943Hu22-20ul | 20ul | £79.00 |
Quantity:
MAA943Hu22-100ul | 100ul | £145.00 |
Quantity:
MAA943Hu22-200ul | 200ul | £193.00 |
Quantity:
MAA943Hu22-1ml | 1ml | £437.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD177; HNA2A; PRV1; HNA-2A; NB1 GP; Polycythemia Rubra Vera 1; Human neutrophil alloantigen 2a; Polycythemia rubra vera protein 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG1 Kappa
Immunogen:
RPA943Hu01-Recombinant Neutrophil Specific Antigen 1 (NB1)
Item Name:
Neutrophil Specific Antigen 1
Potency (Clone Number):
C3
Reactivity:
Po;
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Neutrophil Specific Antigen 1 (NB1) | RPA943Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||